Project Grant HT94252510814
Award Date
9/1/25
Completion Date
8/31/29
Dollars Obligated
$323K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The University of Texas Health Science Center at San Antonio received a $1,565,298 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) on September 1, 2025. The grant will support research to target the METTL3 protein and overcome drug resistance in metastatic clear cell renal cell carcinoma. The research aims to transform healthcare for military service members, veterans, and the broader public through innovative, advanced...
The U.S. Department of Defense's Defense Health Agency has awarded a $1,400,000 Project Grant to The Methodist Hospital Research Institute (HMRI) in Houston, Texas under the Military Medical Research and Development (CFDA 12.420) program. The award, with a performance period from September 15, 2024 through September 14, 2027, will support the "Development of a Novel Therapeutic to Treat DNA Damage Associated with Atypical Burns". This project will focus on advanced biomedical...
The federal Project Grant award of $1,144,500.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support research by the University of Texas MD Anderson Cancer Center to investigate the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma (CCRCC). The award period runs from September 1, 2025, through August 31, 2028. MD Anderson, a...
This Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Texas Southwestern Medical Center. The $1,312,000 grant, with a period of performance from July 1, 2024 to June 30, 2028, will support research on biomarkers and mechanisms of acquired resistance to immunotherapy for renal cell carcinoma. This work aims to improve understanding and treatment of this form of kidney cancer, which is a...
The U.S. Department of Defense's Defense Health Agency awarded a $395,202 Project Grant to The University of Texas Southwestern Medical Center in Dallas, Texas under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "PET IMAGING OF HIF 2A IN RENAL CANCER," supports research to develop new imaging techniques for detecting and monitoring kidney cancer in military personnel and veterans. The three-year award, running from September 1, 2023 to August...
This $834,798 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports PET imaging research of HIF 2A in renal cancer at The University of Texas Southwestern Medical Center in Dallas, Texas. The research project aims to develop new diagnostic and treatment approaches for kidney cancer, which is a key focus area for this Defense Department program. The award will fund basic, translational, and clinical research...
The Department of Defense's Defense Health Agency awarded a $444,125 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Methodist Hospital Research Institute (HMRI) in Houston, Texas. The grant, titled "IDENTIFICATION OF LIAX BINDING PARTNERS FOR PREVENTING RESISTANCE", will fund advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The research will focus on...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $798,673.00 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida to characterize the role of aberrant FGD1 splicing in brain and bone metastasis in clear cell renal cell carcinoma. The award period runs from July 15, 2025 to June 14, 2029. This research aims to advance understanding of the genetic mechanisms underlying...
This $168,042 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research on in vivo targeting of TFE3 dimerization partners in translocation renal cell carcinoma (RCC). The grant was awarded to Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in Boston, Massachusetts, which is a subsidiary of the larger Partners Healthcare System. The research project...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $999,096.00 to The University of Texas Southwestern Medical Center to conduct research on "Targeting DNA Damage Response to Treat Clear Cell Renal Cell Carcinoma." The award period runs from July 1, 2024 to June 30, 2028. The research aims to develop new treatments for clear cell renal cell carcinoma, a type of kidney cancer, by investigating...